Skip to main content

PhRMA, BIO Outline Ideal Off-Label Promotion Regulations

Linda Bentley, a Member in the Mintz Boston office, is quoted in a Bloomberg BNA Health Care Daily Report article highlighting thoughts from two drug industry trade organizations regarding how the Food and Drug Administration (FDA) “re-evaluate how it regulates off-label communication between drugmakers and health-care professionals.” The outline was developed by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO).


Bloomberg BNA Health Care Daily Report